AZN•benzinga•
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
Summary
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing significant survival benefits.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 4, 2025 by benzinga